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A B S T R A C T
Background: Photodynamic therapy (PDT) is a light activated drug therapy that can be used to treat a number of
cancers and precancers. It is particularly useful in its topical form in dermatology but improvement of efficacy is
required to widen its application.
Methods: An ester between aminolaevulinic acid (ALA) and CP94 was synthesised (AP2-18) and experimentally
evaluated to determine whether protoporphyrin IX (PpIX)-induced PDT effectiveness could be improved. A
biological evaluation of AP2-18 was conducted in cultured human primary cells with both PpIX fluorescence and
cell viability (as determined via the neutral red assay) being assessed in comparison to the PpIX prodrugs
normally utilised in clinical practice (aminolaevulinic acid (ALA) or its methyl ester (MAL)) either administered
alone or with the comparator iron chelator, CP94.
Results: No significant dark toxicity was observed in human lung fibroblasts but AP2-18 significantly increased
PpIX accumulation above and beyond that achieved with ALA or MAL administration +/- CP94 in both human
dermal fibroblasts and epithelial squamous carcinoma cells. On light exposure, the combined hydroxypyridinone
iron chelating ALA prodrug AP2-18 generated significantly greater cytotoxicity than any of the other treatment
parameters investigated when the lowest concentration (250 μM) was employed.
Conclusions: Newly synthesised AP2-18 is therefore concluded to be an efficacious prodrug for PpIX-induced
PDT in these dermatologically relevant human cells, achieving enhanced effects at lower concentrations than
currently possible with existing pharmaceuticals.
1. Introduction
Non-melanoma skin cancer (NMSC) is the most common form of
cancer worldwide [1] and its causation is predominantly associated
with excessive solar ultraviolet radiation exposure [2]. NMSC pre-
valence is increasing, with over 80,000 new cases reported in England
in 2008 and NHS skin cancer costs predicted to approach £180M by
2020 [3]. Efficacious, cost-effective and cosmetically acceptable NMSC
treatments are therefore essential.
Traditional treatment of NMSC commonly includes surgical exci-
sion, topical 5-fluorouracil or cryotherapy [4–7]. However, these con-
ventional therapies are not always associated with excellent cosmesis
[4–7] and their appropriateness can be limited, depending on the lo-
cation, size and number of NMSC lesions to be treated [7–9]. Photo-
dynamic therapy (PDT) is a relatively new light-induced drug treatment
for certain types of NMSC that is minimally invasive [4–10]. Delivery of
dermatological PDT can be nurse-led and is safe, with few side effects
beyond treatment effects [5,6,8,9,11]. Several cancers, including
NMSCs and pre-cancers can be treated using PDT [4–13] as well as
some non-malignant skin diseases such as psoriasis and acne [14,15].
PDT uses light to activate a pre-administered drug in the presence of
molecular oxygen to kill diseased, precancerous or neoplastic cells
without harming healthy cells, so healing occurs without scarring [15].
It also has several advantages over some forms of traditional manage-
ment, including the possibility of treating a whole area of field change
at once, the occurrence of good healing on the lower leg, repeated
application to the same area of the skin without the development of
resistance, excellent cosmetic results in highly visible sites without the
need for advanced surgical techniques and its compatibility as an ad-
juvant with other treatment approaches [4–14].
The photosensitiser most commonly used in dermatological PDT is
protoporphyrin IX (PpIX) [8,9,12]. PpIX (a large, water-insoluble
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molecule) can be excited by light of wavelength 635 nm [16]. Skin le-
sions are therefore treated with a topical cream containing a small,
soluble precursor to PpIX (e.g. 5-aminolaevulinic acid (ALA) or the
methyl or hexyl-esters of ALA, methyl-aminolevulinate (MAL) or hexyl-
aminolevulinate (HAL) respectively) [8,9]. These precursors are ab-
sorbed by cells and enzymatically converted into light sensitive PpIX
over a few hours (typically three in clinical application) by the haem
biosynthesis pathway naturally present in all nucleated cells [8,16,17].
This exogenous administration of copious amounts of PpIX precursor
bypasses the primary rate limiting step of this pathway (the synthesis of
ALA from glycine and succinyl-CoA by ALA synthase) [16–18]. This
forces the rest of the pathway to operate at maximal capacity until PpIX
(the immediate precursor to haem) is formed. This naturally light
sensitive compound starts to accumulate over time as the final step in
the pathway (the insertion of Fe2+ into PpIX by ferrochelatase to form
haem) is relatively slow to occur and is thus the secondary rate limiting
step of this pathway [16–18]. It is important to note that haem bio-
synthesis is elevated and less well controlled in cancer cells, which also
possess an altered iron metabolism and dysregulated porphyrin bio-
synthesis enzymes. This makes neoplastic cells more prone to accu-
mulate PpIX more rapidly than normal cells and thus results in this
treatment approach being relatively selective [16,19,20]. The disrupted
tumour surface is also more permeable than healthy skin to the topical
application of the prodrug cream, facilitating PpIX precursor penetra-
tion to where its treatment action is needed most [16,20].
Although effective treatment outcomes associated with excellent
cosmesis have been demonstrated with PpIX-induced PDT conducted in
dermatological lesions where this treatment modality is licensed (ac-
tinic keratosis, Bowen’s disease and BCC) and when the disease remains
superficial [8,21], efforts continue to both increase the efficacy and
extend the applications of dermatological PDT particularly in order to
treat thicker or acrally located conditions [22]. It is already known that
poor penetration into the deeper skin layers can be improved clinically
by employing more lipophilic ALA derivatives (e.g. MAL; Metvix, Gal-
derma, UK) [23–27] or nanoemulsion formulations (e.g. ALA; Ameluz,
Spirit Healthcare, UK) [21] and by performing skin pre-treatments like
the removal of the outer skin layer by tape stripping or scraping
[28–30]. In fact many adaptations to the standard treatment protocol
have been considered to improve efficacy including skin pre-treatment
with the malignant cell differentiation potentiator dimethyl sulfoxide
[31], light dose fractionation [32,33], low fluence rate light adminis-
tration [34] as well as combinations with other techniques (e.g. low
dose Photofrin [35], hyperthermia [36,37], iontophoresis [38] and
bioreductive drugs [39].
A simple pharmacological solution however, utilises the adminis-
tration of an iron chelating agent to temporarily inhibit the final stage
of the haem biosynthesis pathway, which requires iron to convert PpIX
into haem [40]. This pathway is required to convert each of the
commercially available PpIX prodrugs (ALA, MAL and HAL) into the
active photosensitiser PpIX [41] (Scheme 1). Designing a non-toxic,
topically available iron chelator is technically demanding and not all
clinically available iron chelators are suitable for a single topical and
concomitant administration with PpIX-PDT. CP94 (1,2-diethyl-3-hy-
droxypyridin-4-one), is a hydroxypyridinone iron chelating agent,
which has been found however, to have all the parameters required for
this purpose (Scheme 2).
Direct comparison of CP94 and desferrioxamine (DFO; Desferal; an
established iron chelator administered clinically by long infusion for the
treatment of iron overload) in cultured human lung fibroblasts and
epidermal carcinoma cells has previously established [42] that CP94 is
a better enhancer of ALA/MAL-induced PpIX fluorescence than DFO
(and it is already known that DFO is a better enhancer of PpIX-PDT than
EDTA [40]), probably as a result of its lower molecular weight, greater
lipophilicity and neutral charge enabling it to access intracellular iron
pools more rapidly [43]. Further in vitro experimentation has also in-
dicated that CP94 is also a better enhancer of ALA/MAL/HAL-PDT than
the already clinically established iron chelator dexrazoxane (a bis-
dioxopiperazine iron chelating agent similar to EDTA, which can ad-
ministered clinically as an injection alongside doxorubicin to act as a
cardioprotective agent in women receiving treatment for metastatic
breast cancer) [44] and works in a number of different human cell types
[45].
Furthermore, it has been established in vivo in a rat colon model that
CP94 can be used to significantly enhance PpIX levels [46]. Ad-
ditionally on irradiation in this model, CP94+AlA has been found to
produce three times the area of necrosis produced by ALA alone when
delivered at the same time point [46]. Subsequent studies in a rat co-
lonic tumour model determined that iron chelation with CP94 was just
as effective at enhancing ALA-PDT as light dose fractionation when
using comparable parameters [47]. A topical preparation was also de-
rived and was found to be effective at enhancing ALA-PDT in rat skin
Scheme 1. The molecular structures of the active photosensitiser protoporphyrin IX (PpIX) and its existing prodrugs (aminolaevulinic acid (ALA) and its methyl
(MAL) and hexyl esters (HAL)).
Scheme 2. The molecular structure of the existing hydroxypyridinone iron
chelating agent (represented here as its pyridinium salt tautomer), CP94 (1,2-
diethyl-3-hydroxypyridin-4-one).
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[48]. Other investigations of CP94 as an enhancer of PDT have taken
place in rat bladder [49] and rabbit uterus [50]. In addition, the iron
chelating capacity and toxicity of CP94 have been investigated in a
number of iron overloaded and non-overloaded animal models in-
cluding mice [51,52], rats [53,54], guinea pigs [54], rabbits [55] and
Cebus monkeys [53]. Rat studies were found to be predictive of the iron
chelating capacity recorded in primates [53] and the metabolism of
CP94 in guinea pigs was noted to be more similar to that of humans
[54] than studies undertaken in rats as this compound is glucuronidated
by the liver and excreted in urine.
Following these promising experimental findings, topical CP94 ad-
ministration has been investigated in humans as way of improving
PpIX-induced PDT. Dose escalating pilot studies in nodular basal cell
carcinoma (one treatment cycle without lesion debulking) with si-
multaneous topical ALA [56] or MAL administration [11] have already
been conducted. In both cases, CP94 administration was found to be a
safe, effective and feasible treatment modification which did not pro-
duce any additional adverse reactions (no skin irritation during cream
application, no increased erythema following cream application, no
increase in pain visual analogue scores during irradiation and liver
function assessed by blood tests remained unaltered in all patients).
Histological analysis also indicated a significant, increased trend to-
wards complete clearance with increased concentrations of CP94 (up to
40% w/w). It should be noted that efficacy would have been much
improved if normal lesion pre-treatment had been conducted but it was
decided not to do this in these initial clinical studies, so that histological
measurements could be employed as endpoints. CP94 [57] and its close
relation relation, CP20 (1,2-dimethyl-3-hydroxypyridin-4-one; L1; De-
feriprone; DFP) have also been investigated as iron chelating agents in
humans not undergoing PDT, with the latter being studied in detail in
long term investigations of daily oral administration [58,59]. There is
rapid first pass metabolism by the liver following oral administration of
CP20 in humans [60] which limits the clinical effectiveness of these
particular hydroxypyridinone iron chelators for the treatment of con-
ditions of iron overload [61,62], resulting in Deferasirox administration
being utilised, either on its own or in combination with the established
Deferoxamine long infusion treatment regime [63]. These issues are
avoided however, when the iron chelating agent is applied on single
occasions topically to a localised treatment area on the skin during
PpIX-PDT and the subsequent rapid metabolism actually then becomes
an advantage in this application as its effects are short-lived, mini-
mising any potential systemic toxicity.
Effective as it is, as CP94 and its effect on PpIX-induced PDT is al-
ready in the public domain, it therefore cannot be protected sub-
stantially enough to make it a commercially attractive pharmaceutical.
A novel combinational prodrug has therefore been developed, synthe-
sised [64] and tested specially for this purpose here. AP2-18 contains
both the iron chelating capacity of CP94 as well as a PpIX-inducing
prodrug, ALA.
2. Materials and methods
2.1. AP2-18 synthesis
In order to produce a novel pharmaceutical compound for use in
photodynamic therapy (PDT) the iron chelating compound 1,2-diethyl-
3-hydroxypyridin-4-one hydrochloride (CP94) was coupled to proto-
porphyrin IX pro-drug aminolaevulinic acid (ALA) via an ester linkage
to produce the iron chelating pharmaceutical compound AP2-18
(C14H22Cl2N2O5; Scheme 3). We filed a patent application describing
the synthesis of AP2-18 in 2012 and this has been subsequently granted
following scrutiny by numerous individual countries and international
territories [64].
2.2. Cell culture
All media and disposable plastic equipment were purchased from
Sigma (Poole, UK) unless otherwise stated. Human fetal lung fibroblasts
(MRC-5), human skin fibroblasts (84BR) and human epidermal skin
carcinoma cells (A431) were obtained from the European Collection of
Cell Cultures (ECACC, Wiltshire, UK). Cells were maintained in Eagle’s
Minimum Essential Medium (EMEM) supplemented with 10% fetal calf
serum (20% for 84BR cells), 2% (200mM) L-glutamine and 2% (200 U/
ml) penicillin and (200 μg/ml) streptomycin solution. Cells were in-
cubated at 37 °C and 5% CO2 and passaged every 3–5 days as required.
All cell culture work was carried out using aseptic technique in a Class
II biological safety cabinet.
2.3. Initial dark toxicity testing
To establish if the compound AP2-18 possessed any inherent toxic
properties prior to experimentation, a 1000 μM test solution was pre-
pared (the highest concentration used during this investigation) in
standard cell culture medium without phenol red (colourless EMEM).
This was applied to MRC-5 cells (human lung fibroblasts; pre-seeded
into 96 well plates at 5× 104 cells per well and incubated for 24 h in
200 μl of media to obtain 80% confluency), under reduced light con-
ditions and left for 4 h in the dark. Concurrently, further cells were also
exposed to 0.01% (v/v) hydrogen peroxide, which acted as a positive
control or to cell media alone, as a blank control. Cell viability was then
determined using the neutral red uptake (NRU) assay (Fig. 1).
Neutral red is an inert dye actively taken up and stored by viable
(living) cells, an action which is unable to be performed by non-viable
cells, therefore the level of neutral red taken up is directly proportional
to the number of viable cells present following a given exposure
[65,66]. Briefly, the test solutions were aspirated and the cells washed
with 200 μl of 0.3% Bovine Serum Albumin (BSA) in PBS. 100 μl of
0.05% neutral red in PBS was then added to each well for 8min at room
temperature before three more washes (each with 200 μl 0.3% BSA in
PBS) were conducted and 100 μl 70% ethanol containing 0.37% HCl
was applied. Absorbance at 534 nm was then measured with a plate
reader (Synergy HT, BIO-TEK, Germany) with the absorbance at
405 nm being subtracted to determine the number of cells that survived
the PDT treatment.
2.4. PpIX fluorescence accumulation
The level of PpIX (the light sensitive photosensitiser produced from
the prodrugs administered in this form of PDT) accumulation was
monitored using a well-established, previously validated, fluorescence
based assay employed within our laboratory [11,43,44,67]. Briefly,
cells were seeded at 2×104 cells per well in a 96 well plate and left to
adhere overnight. Test solutions were prepared on the day of the assay
by dissolving ALA, MAL, CP94 or AP2-18 into colourless EMEM (i.e.
minus phenol red). The pH of the solutions were checked and adjusted
to physiological pH (pH 7.4) using NaOH (0.5M) as necessary. Solu-
tions were then filter sterilised (0.22 μm, Millipore filter) before being
diluted to the final concentrations and applied to the cells. CP94 (1,2-
diethyl-3-hydroxypyridin-4-one hydrochloride) was kindly provided as
a powder by Professor Hider (King’s College London, UK).
Scheme 3. The molecular structure of the new hydroxypyridinone iron che-
lating ALA prodrug, AP2-18.
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The level of PpIX produced was monitored using a multi-well
fluorescent plate reader (Synergy HT, BIO-TEK, Germany) with a 400
(± 30) nm excitation filter and a 645 (± 40) nm emission filter, with
the level of fluorescence produced being directly proportional to the
level of PpIX present. Readings were taken hourly for 6 h and were
conducted under low light conditions to reduce any photobleaching of
PpIX from occurring.
To evaluate the ability of AP2-18 to cause PpIX accumulation within
cells, a series of concentrations were prepared (250 μM; 500 μM; 1000
μM), which reflect the range previously employed by our group during
similar experimentation with PpIX precursors and iron chelating agents
[11,43,44,67]. These were tested alongside equimolar concentrations of
ALA and CP94 (the components of AP2-18) and methyl aminolevulinate
(MAL) (the licenced prodrug currently widely employed in dermato-
logical PDT in the UK), with all test compounds being investigated in
both human dermal fibroblasts (84BR; Fig. 2) and human epithelial
squamous cell carcinoma cells (A431; Fig. 3).
The results of the statistical analyses which were subsequently un-
dertaken are presented in S1 and S2 (84BR and A431 cells respectively).
2.5. PDT efficacy
To assess the effect of AP2-18 on PpIX- induced PDT efficacy, the
same dermatologically relevant cells were exposed to equimolar con-
centrations of AP2-18, ALA +/- CP94 or MAL +/- CP94 (as described
above) and incubated in the dark for 4 h as this time point yielded
promising results in the fluorescence studies described above. The level
of PpIX accumulation was then quantified as before, prior to irradiation
with red light (37 J/cm2; 635 ± 2 nm; Aktilite, Galderma, UK) as well
as immediately afterwards so that the change in PpIX level (PpIX
photobleaching) could be calculated as a percentage (Fig. 4A and 5A
with dermal fibroblasts and squamous carcinoma cells respectively).
Cell viability was then assessed using the NRU assay (as described
above) with these data being normalised against the blank control cells
(which were exposed to normal cell media) and presented as a
percentage of viable cells (dermal fibroblasts Fig. 4B and squamous
carcinoma cells Fig. 5B). The results of the statistical analyses which
were subsequently undertaken are presented in S3 and S4 (84BR and
A431 cells respectively). These data presented are the mean of three
independent experiments each consisting of three internal repeats of
each condition.
3. Results
Treatment with AP2-18 did appear to result in a very slight reduc-
tion in the number of viable MRC5 cells (Fig. 1), however on statistical
analysis this was not found to be significantly different to control cells
incubated in standard cell culture medium. It was therefore concluded
that AP2-18 does not possess any inherent toxicity and could be tested
for efficacy in dermatologically pertinent cells.
Accumulation of PpIX fluorescence produced by each of the pro-
drugs investigated (AP2-18, ALA +/- CP94 or MAL +/- CP94) in-
creased over time in each cell type examined; human dermal fibroblasts
(Fig. 2) and human epidermal squamous carcinoma cells (Fig. 3). AP2-
18 was also found to significantly increase PpIX accumulation in both
dermatological cell types, above and beyond that achieved with ALA or
MAL administration either alone or in combination with the com-
parator iron chelating agent, CP94. This enhancement was most con-
sistent at incubation times of 4 h and greater in the dermal fibroblast
cell type. ALA was also observed to be more effective at producing
PpIX, than the same concentration of MAL administered in both the cell
types investigated. Additionally higher levels of PpIX fluorescence were
generally recorded in the dermal fibroblasts than the squamous carci-
noma cells. As these PpIX fluorescence studies indicated that AP2-18
had the potential to substantially improve PpIX-induced PDT, further
experimentation was undertaken to determine whether these sig-
nificant increases in PpIX accumulation could be translated into in-
creased cell kill on irradiation.
Substantial PpIX photobleaching (i.e. a reduction in PpIX fluores-
cence during light irradiation) was observed in the vast majority of the
treatment groups investigated (Figs. 4A and 5 A). This demonstrated
that PpIX was being “consumed” during the light treatment through an
unwanted reaction (as PpIX was being transformed into a non-PDT
active photoproduct through interaction with singlet oxygen being
produced by the PDT reaction itself) and thus indicated that PDT was
successfully occurring within both cell types investigated. Complete
PpIX photobleaching was rarely achieved with the particular treatment
parameters employed here however and this may indicate increased
PDT effects could have been delivered if a bigger light dose had been
employed. However, with the exception of the MAL only treatment
groups, there was a general trend of greater photobleaching being ob-
served with increasing doses of the PpIX precursors being administered.
Analysis of the cell viability results revealed that both the blank
control and hydrogen peroxide positive control groups performed as
anticipated in both cell types, producing little cytotoxicity and con-
siderable cell death respectively. In human dermal fibroblasts (Fig. 4B)
the use of the iron chelator CP94, improved the PDT effect of both ALA
and MAL in a concentration dependent manner and AP2-18 was found
to be significantly better than all the MAL doses and all the ALA doses
except the highest (1000 μM) considered, at reducing cell viability
following PDT even when the lowest concentration of AP2-18 (250 μM)
was employed (S3). At 1000 μM ALA and with the higher doses of CP94
administered in combination with ALA or MAL, when statistical sig-
nificance was not achieved, the level of cell kill produced by AP2-18
was equivalent to that observed with the other treatment groups. These
neutral red viability assay results also appeared to correlate with the
PpIX fluorescence and photobleaching results noted above, with ALA
again appearing more effective than MAL in terms of cell kill in this cell
type. Very similar trends and significant reductions in cell viability
were also observed in the human epithelial squamous carcinoma cells
(Figs. 5B & S4), where once again AP2-18 and ALA+CP94 were the
Fig. 1. Neutral red uptake assay to assess the level of inherent (dark) toxicity
possessed by AP2-18. AP2-18 was not found to be inherently toxic to human
lung fibroblasts (MRC-5) when compared to control cells only exposed to cell
medium. Exposure to the 0.01% (v/v) hydrogen peroxide positive control
conditions resulted in a significant (P < 0.001; Student’s t-test) reduction in
cell viability.
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most effective PDT protocols tested producing not statistically dissim-
ilar results from one another but substantially better effects than the
ALA or MAL congeners administered alone. The addition of the hy-
droxypyridinone iron chelating agent CP94, either separately to ALA
administration or via the new combinational iron chelating ALA pro-
drug AP2-18, therefore significantly improved PpIX-PDT in these
human skin cells.
4. Discussion
AP2-18 has therefore been found to significantly increase PpIX ac-
cumulation in both human dermal fibroblasts (84BR) and human epi-
thelial squamous carcinoma cells (A431) above and beyond that
achieved with ALA or MAL administration either alone or in combi-
nation with the iron chelator CP94. Furthermore it has also been found
that AP2-18 produced significantly increased PDT cell kill on irradia-
tion and achieved this effect at lower concentrations than possible with
ALA or MAL with or without administration of the iron chelator CP94 in
these cells of dermatological origin. In the squamous carcinoma cells,
AP2-18 was demonstrated to be equally effective as ALA+CP94 ad-
ministration, demonstrating the biological effectiveness of the newly
synthesised compound.
AP2-18 has therefore been demonstrated in vitro to be an efficacious
and improved prodrug for PpIX-induced PDT, which warrants further
detailed study. Although we know the toxicity profile, metabolism
route and efficacy of all the active components of AP2-18 (ALA, MAL,
HAL, PpIX and CP94) in a variety of animal models as well as human
beings, a portion of this work (i.e. key experiments and doses) will need
to be repeated with the new combinational prodrug AP2-18 to i) ensure
future patient safety, ii) gain regulatory approval and iii) determine the
most effective treatment protocol for clinical application.
These results indicate that AP2-18 is able to enter human cells and
additionally, because increased PpIX production results, it can be hy-
pothesised that cytosolic esterases are able to break the bond between
the PpIX prodrug and CP94 molecule, so that these constituent parts
can function effectively. Once split the potential toxicity profile and
metabolism route of the compounds should be as previously observed.
Experimentation will have to be undertaken in animals however, to
confirm this when using the new combination prodrug AP2-18 is uti-
lised as the starting point. Additionally, topical availability and PDT
effectiveness will have to be confirmed in suitable animal models and
although theoretically this will not be an issue, it will still need to be
demonstrated through future research before clinical evaluation can be
considered. The topical availability of AP2-18 would probably be best
evaluated in an animal model such as pig skin prior to conducting
clinical studies. These evaluations could mirror the successful approach
adopted by Maisch et al. (2010), when they evaluated PpIX distribution
of a topically applied nanoemulsion-based formulation of BF-200 ALA
in a porcine ex vivo skin model in comparison to MAL [68]. The amount
of work required to do all this will be significantly less than with other
agents at this stage of development however, because of the extensive
research and clinical experience already gained with the active com-
ponents of this new combinational prodrug [11,42–57,67,69,70].
AP2-18 is effectively a combination of ALA and the hydro-
xypyridinone iron chelating compound CP94, which have been linked
via an ester linkage. However, our biological evaluation in these der-
matologically derived cell types, indicate that this linked compound
appears to have a similar or better activity profile than a PpIX precursor
administered separately in combination with CP94 and at lower doses
in many cases. It might have been reasonably expected that delivering
ALA and CP94 in a linked format (rather than separately) may have
altered the way the compounds enter cells in potentially a negative
Fig. 2. Accumulation of PpIX fluorescence (+/- the standard error of the mean) in human dermal fibroblasts (84BR) over time following exposure to i) novel
compound AP2-18, ii) ALA alone, iii) ALA+ the iron chelator CP94, iv) MAL alone and v) MAL+ the iron chelator CP94. Statistical comparison provided in S1.
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manner; bigger molecules tend to not enter cells as effectively as
smaller molecules and may use different transporters. In fact, even the
molecularly very similar structures of ALA and MAL prodrugs are
thought to enter cells via different membrane transporters in different
cell types but in the A431 squamous carcinoma cells employed here,
cell uptake of both ALA and MAL is thought to be via Gat-3 (GABA)
transporters [71]. The cellular uptake mechanism of AP2-18 has not
been investigated here but there was no guarantee that the new entity
would be able to produce even the same level of results as ALA and
CP94 administered as separate agents and so these in vitro findings are
encouraging. These findings are also supported to some extent by the
work of Battah et al. [72], who made AP2-18 (compound 7a [72]) as
part of a large series of hydroxypyridinone and 5-aminolaevulinic acid
(HPO-ALA) conjugates that they have compared with ALA activity,
subsequent to the publication of our patent [64]. Although this pub-
lished experimentation cannot be directly compared to the results
presented here due to methodological differences such as different cell
lines, blue light and physiological levels of iron supplementation being
employed, they concluded that passive diffusion appeared to be the
main mechanism of cellular entry for the majority of the HPO-ALA
conjugates that they studied and that ester binding the hydro-
xypyridinone to ALA via longer hydrocarbon linkages of up to n=10
produced greater PpIX fluorescence over the same incubation time
period of 6 h. Furthermore, these observations translated into increased
phototoxicity being detected with the MTT assay on illumination and
no appreciable HPO-ALA dark toxicity was observed [72]. There is
therefore increasing experimental evidence that HPO-ALA conjugates
may be a very useful way of enhancing the efficacy of the clinical ap-
plication of PpIX-PDT.
It is actually very difficult to predict how the linked format of PpIX
precursor to an iron chelating hydroxypyridinone might affect the in-
nate cellular biochemistry relied upon to produce the natural photo-
sensitiser PpIX. ALA is normally formed by ALA synthase in the mi-
tochondrion before entering the portion of the haem biosynthesis
pathway that occurs in the cytosol. The later step of insertion of iron
into the PpIX porphyrin ring to form haem occurs in the mitochondrion
[16]. In order to influence this pathway in such a way that PpIX ac-
cumulates, the iron chelator needs to be able to diminish mitochondrial
levels of iron either directly or indirectly. However, AP2-18 first needs
to be separated into its active components by esterases present in the
cytosol in a similar manner to MAL [73] and Battah et al. hypothesise
that a longer hydrocarbon linkage improves the cellular uptake of HPO-
ALA conjugates by making them less hydrophilic [72], however gen-
erally smaller molecules enter the skin more easily. In addition, in
theory it might seem better to deliver the CP94 before the ALA, in order
to chelate the iron prior to producing the PpIX, whereas delivering the
agents in a linked format means that the agents are delivered simulta-
neously. However, it appears quite the opposite is true both here with
the new AP2-18 combined structure and in previous work in animals
with ALA and CP94 administration undertaken at different time points
[46].
Furthermore, the iron chelator CP94 is bidentate and it therefore
takes three CP94 molecules to bind one Fe2+ ion. In addition to this, in
the haem biosynthesis pathway two molecules of ALA dimerize to form
porphobilinogen after which four molecules of the latter are condensed,
rearranged and cyclised to produce uroporphyrinogen III; this is then
converted into protoporphyrin IX via coproporphyrinogen III.
Therefore, eight molecules of ALA are needed to form one PpIX mole-
cule, which binds to one Fe2+ ion to form one molecule of haem [16].
The theoretical ratio of ALA : CP94 required per Fe2+ ion would,
Fig. 3. Accumulation of PpIX fluorescence (+/- the standard error of the mean) in human epithelial squamous carcinoma cells (A431) over time following exposure
to i) novel compound AP2-18, ii) ALA alone, iii) ALA+ the iron chelator CP94, iv) MAL alone and v) MAL+ the iron chelator CP94. Statistical comparison provided
in S2.
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therefore, in simplistic biosynthetic terms, be 8 ALA : 3 CP94, i.e. over
twice as much ALA as CP94. Despite this, the equal quantities of ALA
and CP94 delivered via the combined AP2-18 precursor compound
appeared highly effective in the cell types investigated here and could
theoretically be due to greater levels of CP94 delivered via AP2-18
administration, draining intracellular iron stores, making haem for-
mation from PpIX less likely to occur and thus augmenting PpIX levels
as well as leading to greater PDT effects on irradiation as observed here.
In our previous investigations of ALA and CP94 co-administration
[698], where we controlled the amounts of iron supplied to the cells in
the tissue culture media, we found that iron chelation had a highly
positive effect on PpIX accumulation, which far outweighed any lim-
iting factor that reduced iron availability might have on subsequent free
radical production on irradiation, and this led to enhanced PDT effects
being produced following the administration of an iron chelating agent.
It is clear however, that we are manipulating a highly complex bio-
chemical environment, which can vary depending on cell type and in-
nate iron status.
It is therefore concluded that a novel, combined hydroxypyridinone
iron chelating ALA prodrug (AP2-18) has been synthesised and de-
monstrated to be more effective at generating PDT effects when in-
vestigated in vitro in human dermatological cells, than existing clini-
cally utilised PpIX prodrugs. With further investigation, the significant
increases in cytotoxicity following PpIX-induced PDT conducted with
AP2-18, could potentially be translated into clinical PDT settings to
produce substantial benefits for patients. This could either take the
form of reducing the number of treatment cycles currently required to
treat existing licensed indications or alternatively improve outcomes in
dermatological applications where a more effective PDT treatment re-
gime is still required.
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